血浆二胺氧化酶水平预测乙型肝炎病毒相关失代偿期肝硬化

StephenW

Plasma diamine oxidase level predicts 6-month readmission for patients with hepatitis B virus-related decompensated cirrhosis

    Feng-Cai Li, Yu-Chen Fan, Yue-Kai Li & Kai Wang

Virology Journalvolume 16, Article number: 115 (2019) | Download Citation
Abstract
Background and aims

Hepatitis B virus-related decompensated cirrhosis is difficult to cure but has a high readmission rate due to multiple complications. Our aim was to investigate the diagnostic potential value of plasma diamine oxidase (DAO) for 6-month readmission of patients with HBV-related decompensated cirrhosis.
Methods

A total of 135 patients with HBV-related decompensated cirrhosis were prospectively collected at the onset of discharge of hospital, and then were followed up for at least 6 months with the readmission as the primary outcome. The plasma DAO level was measured using enzyme linked immunosorbent assay. In addition, 120 age and sex matched patients with HBV-related compensated cirrhosis were included as controls.
Results

A total of 36 patients (36.7%) with decompensated cirrhosis admitted to hospital during the 6-month follow up. The plasma DAO level of readmission group [21.1 (14.5; 29.0) ng/ml] was significantly higher than that in the non-readmission group [12.7 (9.3; 18.0) ng/mL, P < 0.001]. Multivariate analysis showed that the plasma DAO level (HR = 1.102, P < 0.05) and hepatic encephalopathy (HE) (HR = 5.018, P < 0.05) were independent factors for 6-month readmission of decompensated cirrhosis. DAO level showed higher area under the curve of receiver operating characteristic (AUROC) than HE (0.769 vs. 0.598, P < 0.05) and Child-Pugh-Turcotte (CPT) score (0.769 vs. 0.652, P < 0.05) for predicting 6-month readmission rate, with the best cut-off value as 19.7 ng/mL. Furthermore, plasma DAO level (HR = 1.184, P < 0.05) was an independent factor and has the higher AUROC than CPT score for the onset of recurrent HE (0.905 vs. 0.738, P < 0.05) during the 6-month follow up.
Conclusions

Plasma DAO level > 19.7 ng/mL predicts high rate of 6-month readmission in patients with HBV-related decompensated cirrhosis.

StephenW

血浆二胺氧化酶水平预测乙型肝炎病毒相关失代偿期肝硬化患者6个月再入院

李凤才，范玉辰，李悦凯，王凯

Virology Journalvolume 16，货号：115（2019）|下载引文
抽象
背景和目标

乙型肝炎病毒相关的失代偿性肝硬化难以治愈，但由于多种并发症而具有高的再入院率。我们的目的是调查血浆二胺氧化酶（DAO）对HBV相关失代偿性肝硬化患者6个月再入院的诊断潜在价值。
方法

共有135例HBV相关失代偿期肝硬化患者在出院开始时前瞻性收集，随后随访至少6个月，其中再入院为主要结果。使用酶联免疫吸附剂测量血浆DAO水平。此外，将120名年龄和性别匹配的患有HBV相关代偿性肝硬化的患者作为对照。
结果

在6个月的随访期间，共有36名患有失代偿期肝硬化的患者（36.7％）住院。再入院组血浆DAO水平[21.1（14.5; 29.0）ng / ml]显着高于非再入院组[12.7（9.3; 18.0）ng / mL，P <0.001]。多变量分析显示，血浆DAO水平（HR = 1.102，P <0.05）和肝性脑病（HE）（HR = 5.018，P <0.05）DAO水平在接受者操作特征曲线（AUROC）下显示出比HE更高的面积（用于预测6个月再入率的0.769对0.598，P <0.05）和Child-Pugh-Turcotte（CPT）评分（0.769对比0.652，P <0.05），最佳临界值为19.7ng / mL。此外，血浆DAO水平（HR = 1.184，P <0.05）是一个独立因素，并且在6个月的随访期间，复发性HE发病的AUROC高于CPT评分（0.905对比0.738，P <0.05）。 。
结论

血浆DAO水平> 19.7 ng / mL预测HBV相关失代偿期肝硬化患者的6个月再入院率很高。

StephenW

https://virologyj.biomedcentral. ... 6/s12985-019-1219-4